Vioxx Hearing Witnesses Push For Independent Drug Safety Office
This article was originally published in The Tan Sheet
Executive Summary
The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)
You may also be interested in...
MHRA Has “Significant Failings” – UK Committee Report
Britain's health authority needs an independent review to determine whether its current decision-making processes adequately reflect patients' health needs, the UK House of Commons Health Committee says
MHRA Has “Significant Failings” – UK Committee Report
Britain's health authority needs an independent review to determine whether its current decision-making processes adequately reflect patients' health needs, the UK House of Commons Health Committee says
MHRA Has “Significant Failings” – UK Committee Report
Britain's health authority needs an independent review to determine whether its current decision-making processes adequately reflect patients' health needs, the UK House of Commons Health Committee says